<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564937</url>
  </required_header>
  <id_info>
    <org_study_id>SCT510A-A101</org_study_id>
    <nct_id>NCT04564937</nct_id>
  </id_info>
  <brief_title>The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)</brief_title>
  <official_title>A Multicenter, Open-label, Multi-dose, Phase I / II Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Efficacy and Pharmacodynamic Characteristics of SCT510A in the Patients With Wet Age-related Macular Degeneration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients&#xD;
      with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal&#xD;
      antibody（SCT510A）&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 6, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting toxicity(DLT)</measure>
    <time_frame>From Day 0 up to Day 14</time_frame>
    <description>Incidence of dose-limiting toxicities up to the Day 14 visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose(MTD）</measure>
    <time_frame>From Day 0 up to Day 140</time_frame>
    <description>Maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>From Day 0 up to 84 days</time_frame>
    <description>Change of SCT510A drug concentration in the blood with time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From Day 0 up to 84 days</time_frame>
    <description>The maximum blood concentration after SCT510A drug enters the bloodstream</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From Day 0 up to 84 days</time_frame>
    <description>Time to the Maximum Concentration of SCT510A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From Day 0 up to 84 days</time_frame>
    <description>Elimination Phase Half-life of SVT510A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>From Day 0 up to 84 days</time_frame>
    <description>Detection of free VEGF concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From Day 0 up to 112 days</time_frame>
    <description>Positive rate of ADA and NAb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central retina thickness（CRT）</measure>
    <time_frame>From Day 0 up to 140 days</time_frame>
    <description>Changes in CRT compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular edema volume</measure>
    <time_frame>From Day 0 up to 140 days</time_frame>
    <description>Changes in Macular edema volume compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity（BCVA）</measure>
    <time_frame>From Day 0 up to 140 days</time_frame>
    <description>Changes in BCVA compared to the baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>SCT510A dose level 1 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCT510A(0.625mg), Vitreous injection, injection once every 4 weeks，three times continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCT510A dose level 2 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCT510A(1.25mg), Vitreous injection, injection once every 4 weeks，three times continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCT510A dose level 3 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCT510A(2.0mg), Vitreous injection, injection once every 4 weeks，three times continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCT510A dose level 4 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCT510A(2.5mg), Vitreous injection, injection once every 4 weeks，three times continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCT510A</intervention_name>
    <description>SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT</description>
    <arm_group_label>SCT510A dose level 1 treatment</arm_group_label>
    <arm_group_label>SCT510A dose level 2 treatment</arm_group_label>
    <arm_group_label>SCT510A dose level 3 treatment</arm_group_label>
    <arm_group_label>SCT510A dose level 4 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form;&#xD;
&#xD;
          2. Age≥45 years，≤80 years，male or femal;&#xD;
&#xD;
          3. The study eye must meet the following criteria： Diagnosis of wAMD； Primary or&#xD;
             recurrent active subfoveal or parafoveal choroidal neovascularization (CNV) lesions&#xD;
             secondary to AMD； Total area of all types of lesions ≤12 optic disc areas（30mm2）；&#xD;
             Best-corrected visual acuity of the study eye 70 letters or worse(Snellen equivalent&#xD;
             of 20/40 or worse)； No optometric media opacity and pupil shrinkage.&#xD;
&#xD;
          4. Best-corrected visual acuity of the fellow eye 19 letters or better（Snellen equivalent&#xD;
             of 20/400 or better）.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The study eye suffers structural damage of retinal which involves fovea，and the&#xD;
             investigator assess that there is a risk of retinal detachment；&#xD;
&#xD;
          2. Significant afferent pupillary defect (APD) in the study eye；&#xD;
&#xD;
          3. The study eye has no lens( except intraocular lens) or posterior capsular rupture of&#xD;
             the lens；&#xD;
&#xD;
          4. In addition to AMD，there are other obvious eye diseases/conditions，such as&#xD;
             pseudoexfoliation syndrome，rhegmatogenous retinal detachment，macular hole，diabetic&#xD;
             retinopathy and diabetic macular disease which need to be treated；&#xD;
&#xD;
          5. CNV caused by other causes other than wAMD, such as vascular stripe disease, ocular&#xD;
             histoplasmosis, case myopia, trauma, etc；&#xD;
&#xD;
          6. Uncontrolled glaucoma in the study eye (defined as IOP≥25mmHg after antiglaucoma&#xD;
             treatment),or recevied glaucoma filtering surgery；&#xD;
&#xD;
          7. History of vitreous hemorrhage in the study eye within 2 months before the first&#xD;
             administration；&#xD;
&#xD;
          8. Active inflammation or infection in either eye, such as conjunctivitis,keratitis,&#xD;
             scleritis, endophthalmitis, or uveitis，ect；&#xD;
&#xD;
          9. Previous intraocular surgery ，or laser therapy for wAMD(as photodynamic&#xD;
             therapy,transpupillary thermotherapy,etc.) in the study eye within 3 months before the&#xD;
             first administration；&#xD;
&#xD;
         10. Previous intraocular or periocular injection of anti-VEGF or corticosteroid drugs&#xD;
             (such as ranibizumab, bevacizumab, conbercept, aflibercept, brolucizumab, pegaptanib&#xD;
             sodium, anecortave acetate, triamcinolone acetonide, etc.) in either eye within 3&#xD;
             months before the first administration；&#xD;
&#xD;
         11. History of allergy to fluorescein sodium or indocyanine green；&#xD;
&#xD;
         12. PLT≤100×109/L；thrombin time and prothrombin time exceed the upper limit of normal&#xD;
             range (based on the laboratory normal value of clinical trial institution), and the&#xD;
             abnormality is clinically significant according to the evaluation of the&#xD;
             investigators；&#xD;
&#xD;
         13. Abnormal liver and kidney function；&#xD;
&#xD;
         14. Uncontrolled blood pressure control，systolic blood pressure≥160mmhg ,or diastolic&#xD;
             blood pressure≥100mmhg；&#xD;
&#xD;
         15. History of surgery within one month before the first administration, or current&#xD;
             non-healing wound, ulcer, or fracture，etc；&#xD;
&#xD;
         16. Patients with any of the following serious systemic diseases，such as serious mental,&#xD;
             neurological, cardiovascular, respiratory and other system diseases and malignant&#xD;
             tumors, systemic immune system diseases, diabetes mellitus with uncontrolled blood&#xD;
             sugar(HbA1c&gt;10%), disseminated intravascular coagulation and significant bleeding&#xD;
             tendency；&#xD;
&#xD;
         17. Suffering from systemic infectious diseases requiring oral, intramuscular or&#xD;
             intravenous administration；&#xD;
&#xD;
         18. Pregnant, lactating women and the patients who can not take contraceptive measures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Guo</last_name>
    <phone>+86-10-58628288-9138</phone>
    <email>ming_guo@sinocelltech.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

